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Abstract
Objective—To describe relationship between cord blood (representing fetal) myo-inositol
concentrations and gestational age (GA) and to determine trends of blood concentrations in
enterally and parenterally fed infants from birth to 70 days of age.
Design/Methods—Samples were collected in 281 fed or unfed infants born in 2005 and 2006.
Myo-inositol concentrations were displayed in scatter plots and analyzed with linear regression
models of natural log-transformed values.
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Results—In 441 samples obtained from 281 infants, myo-inositol concentrations varied from
nondetectable to 1494 μmol/L. Cord myo-inositol concentrations decreased an estimated 11.9%
per week increase in GA. Postnatal myo-inositol concentrations decreased an estimated 14.3% per
week increase in postmenstrual age (PMA) and were higher for enterally fed infants compared to
unfed infants (51% increase for fed vs. unfed infants).
Conclusions—Fetal myo-inositol concentrations decreased with increasing GA. Postnatal
concentrations decreased with increasing PMA and were higher among enterally fed than unfed
infants.

Introduction
Author Manuscript

Inositol is present throughout the body and particularly in the central nervous system as an
intracellular free sugar alcohol [1]. At least 90% is myo-inositol, the major stereoisomer in
the body. Myo-inositol is additionally a constituent of a number of inositol-phosphates,
glycolipids, glycoproteins, and particularly phosphoinositides. The most common
phosphoinositide, phosphatidylinositol, is a structural component of various membranous
structures and a component of lung surfactant phospholipids. Cord blood concentrations of
myo-inositol are high in the early gestation and decrease with increasing gestation [2, 3].
Postnatal blood concentrations of myo-inositol increase through day 2 and then decrease
with increasing postnatal age [3].

Author Manuscript

Preterm colostrum has higher myo-inositol concentrations than mature preterm milk
(average 2.24 mmol/L [40.36 mg/dL] vs. 1.34 mmol/L, respectively, in one study and 4.23
mmol/L vs. 1.86 mmol/L in another study) [4–6]. A minimum of 0.96 mg/100 kJ (4 mg/100
kcal) myo-inositol was recommended by the American Academy of Pediatrics Committee
on Nutrition in 1976 for milk-based formula [7]. A maximum of 9.56 mg/100 kJ (40 mg/100
kcal) was recommended by the American Academy of Pediatrics in 2004 following a
recommendation from the Life Sciences Research Organization [8]. Over the ensuing years,
increasing amounts of myo-inositol have been added to formulas and to breast milk
fortifiers; however, no intravenous product has been developed. Two studies conducted in
the 1980s have shown higher postnatal concentrations of myo-inositol in enterally fed
preterm infants than in those receiving parenteral nutrition exclusively [4, 6].
J Perinatol. Author manuscript; available in PMC 2021 February 18.
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In preparation for a large multicenter trial of myo-inositol to prevent retinopathy of
prematurity to be conducted by the Eunice Kennedy Shriver National Institute of Child
Health and Human Development Neonatal Research Network [9], a series of pilot studies
[10, 11] were planned to select an appropriate dose and increase understanding of the
pharmacokinetics of this endogenous sugar alcohol in the very low birth weight infant. This
preparatory observational study was designed [1] to describe the relationship between cord
blood (representing fetal) concentrations and gestational age (GA) and [2] to determine
trends of blood myoinositol concentrations in enterally and parenterally fed infants from
birth to 70 days of age, which was the planned duration of myo-inositol administration in the
trial.

Methods
Author Manuscript
Author Manuscript

This was an observational study to describe the concentrations of myo-inositol in cord and
postnatal blood at various ranges of GA and postmenstrual age (PMA) without myo-inositol
supplementation and how they are affected by oral feeding. Residual serum or plasma
samples from infants born at GA of 24–42 weeks and postnatal age of 0–70 days were
scavenged from clinical laboratories and linked to deidentified demographic (gender, GA,
size for GA, postnatal age) and feeding data (formula, human milk [HM], supplements,
intravenous fluids, all without myo-inositol). Characteristics of the sample were recorded
(source, type of anticoagulant [none, ethylenediamine-tetra-acetic acid {EDTA}, lithium
heparin], time from collection to storage), and a unique code was assigned. Samples of
serum/plasma were batched, frozen, and sent to the Pediatric Pharmacology Research Unit
at the University of Utah. Myo-inositol was measured by high pressure liquid
chromatography in 50 μL of serum or plasma; this method analyzes total free myo-inositol.
This assay is linear from 0 to 1000 μmol/L with a correlation coefficient of 0.997 and a
lower limit of detection of 50 μmol/L [12]. Concentrations ranging 50–99 μmol/L were
reported as below quantifiable limit (BQL). The chromatographic peak of myo-inositol
immediately follows that of glucose; however, the chromatographic curve returns to baseline
except for very high glucose concentrations, thereby yielding accurate and precise
measurements of myo-inositol using the peak area ratio of inositol to internal standard. The
day-to-day coefficient of variation was 13% for 50 μmol/L, 7% for 100 μmol/L, and <3% for
300 and 700 μmol/L. Intraday coefficient of variation was <2% for values 100–700 μmol/L.
The lowest quantified reported value in this study was 100 μmol/L. Myo-inositol
concentrations are stable when stored at room temperature for up to 1week and are
unaffected by anticoagulation with lithium heparin, or EDTA [12].

Author Manuscript

A target of seven samples was sought for each of four GA groups, at five postnatal age
ranges. In addition, for the youngest two GA groups, a similar target sample was sought in
the four feeding categories explained in Table 1. Nothing per os (NPO) was defined as no
enteral feeding for the previous 72 h. The half-life of myo-inositol in preterm infants has
been estimated as 5.22 h for single intravenous administration data and 7.90 h for multiple
intravenous administration data [10, 11]. We are not aware of any pharmacokinetic study of
myo-inositol administered enterally in neonates. In adults, the serum concentration of myoinositol after a single enteral dose peaks at 3 h and is back to baseline after 25 h [13]. Thus,
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after 72 h NPO (i.e., 6 half-lives beyond 25 h), the majority of myo-inositol administered
enterally is likely to have been eliminated.
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Data analyses included descriptive statistics for myo-inositol concentration, including
frequencies of results where myo-inositol was not detected (ND), BQL and quantifiable as
well as first quartile, median, and third quartile values for the quantifiable values.
Nonparametric locally weighted scatter-plot smoother (LOESS) curves and associated 95%
confidence intervals were plotted over scatter plots to descriptively assess the profile of
myo-inositol concentrations by GA for cord samples and by PMA for postnatal samples. For
cord and postnatal samples separately, the natural log-transformed concentration was
modeled employing left-censoring techniques to account for values that were not
quantifiable. The left censoring assumes that the nonquantified values are below 100 μmol/L
but are not assumed to be a specific value. For cord samples, natural log-transformed inositol
concentration was modeled as a function of GA. For postnatal samples, natural logtransformed inositol concentration was modeled as a function of GA, PMA, and feeding
category (fed vs. NPO) with a random effect for infant to account for correlation between
observations within infant. The final model was selected to fit available data best as
determined by the Akaike information criterion (AIC). Results include the parameter
estimate and its standard error (SE) and the percentage change per week or for feeding vs.
NPO. Predictive curves resulting from the model were plotted over scatter plots to
descriptively assess the profile of myo-inositol concentrations by GA for cord samples and
by PMA for postnatal samples. Sensitivity analyses using linear regression models with
imputed values of log-transformed postnatal concentrations instead of left censoring were
also performed that explored quadratic and cubic terms of age and size for GA. Statistical
analysis was conducted using SAS version 14.2; in particular PROC NLMIXED for the leftcensoring models (SAS Institute, Inc., Cary, NC).
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The study was reviewed and approved by the IRB at each participating center. Approval with
waiver of consent was granted for six of the seven centers, whereas written consent was
obtained in one center.

Results
Demographics

Author Manuscript

The study recruited 281 infants in calendar years 2005–2006. The range of GA at birth was
24–42 weeks with a median GA of 29 weeks. Among the infants sampled, 47% were
female. Information on race and ethnicity were incomplete and thus not reported. Among the
441 samples, 1 sample was obtained in 193, 2 samples in 52, 3 samples in 18, and 4–8
samples in 18 infants. The range of PMA for sample collection extended from 22 to 45
weeks (Table 2).
Myo-inositol concentrations

Myo-inositol was measured in serum (18% of the samples) or plasma (74% heparin, 8%
EDTA) obtained from 34 cord samples and 407 infant samples (Table 2). Myo-inositol was
ND in 84 (19%) samples while concentrations were BQL in 63 (14%) samples. The overall
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distribution of natural log-transformed myo-inositol concentrations is approximately
consistent with a normal distribution that is left-censored at 100 μmol/L (Supplementary Fig.
1).
A total of 34 cord samples were obtained and analyzed with myo-inositol concentrations
appearing to decrease as gestation advanced from 24 to 42 weeks; the relationship was not
linear, with progressive flattening of the curve when plotted on a linear scale
(Supplementary Table 1, Fig. 1). The parameter estimate for GA was −0.13 (SE = 0.04),
corresponding to a 11.9% decrease in cord myo-inositol concentrations for each 1 week
increase in GA (P value = 0.003) (Table 3).
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A total of 407 postnatal samples were analyzed, with a general trend of myo-inositol
concentrations decreasing as PMA increased; the relationship was not linear, with
progressive flattening of the curve when plotted on a linear scale (Supplementary Table 1,
Fig. 2). The adjusted geometric mean for myo-inositol concentration of samples obtained
from enterally fed infants are estimated to be increased by 50% compared to samples from
the NPO infants.
The parameter estimate for PMA was −0.15 (SE = 0.02) corresponding to a 14.3% decrease
in postnatal myo-inositol concentrations for each 1 week increase in PMA. The adjusted
geometric means for myo-inositol concentration (μmol/L) for samples obtained from fed
infants were increased by ~50% compared to samples from the NPO infants.
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Sensitivity analyses using imputed values of postnatal myo-inositol concentrations provided
consistent results with respect to significance of parameter estimates and did not show any
evidence of an effect of size for GA nor of a cubic or quadratic relationship between age and
natural log-transformed myo-inositol concentration. As a note, only six samples were from
small for GA infants, among which three were BQL, one was ND, and two were quantified.

Discussion

Author Manuscript

In this study, we observed a large range of mixed cord blood myo-inositol concentrations,
which decreased with increasing GA. Postnatal myo-inositol concentrations decreased after
3 weeks of postnatal age. A linear model of the natural log-transformed concentration with
left censoring of nonquantified values fit available data best as determined by AIC criterion
(not shown). To our knowledge, this study reports results from the largest dataset of
postnatal myo-inositol concentrations in newborn infants. Postnatal concentrations
decreased with increasing PMA. Concentrations were higher among infants who were
feeding compared to those who remained NPO. Preliminary results of this study were used
in establishing the dosing of myo-inositol in the randomized controlled trial that was later
conducted by the NICHD Neonatal Research Network [9].
These data are in agreement with previous publications, which showed a progressive
decrease in serum myo-inositol concentration with increasing GA and postnatal age and
higher concentrations in patients receiving enteral feedings compared to those receiving
parenteral nutrition exclusively [2, 4, 14]. No significant relationship was found between
myo-inositol cord blood concentrations and size for age, possibly due to the small sample
J Perinatol. Author manuscript; available in PMC 2021 February 18.
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size for growth restricted infants and the high proportion of those values that were not
measurable. Intrauterine growth restriction is associated with increased myo-inositol
concentrations in sheep and human placenta and neonatal human urine [15–19].
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Myo-inositol is synthesized in many tissues by cyclisation of glucose-6-phosphate into myoinositol-1-phosphate, which is dephosphorylated by inositol-1-phosphatase to produce
inositol [20]. Most inositol is located intracellularly as the free myo-inositol stereoisomer. In
addition, it is present as a component of myo-inositol-containing physiological molecules
[20–22]. Since myo-inositol has been identified as a second messenger of insulin, it has been
proposed as a dietary supplement for women with gestational diabetes [23]. A systematic
review of randomized trials found that the only benefit of maternal myo-inositol
supplementation was a reduced risk for neonatal hypoglycemia [23]. The Na+/myo-inositol
cotransporter (SMIT1) has a critical role in developing neural control system, peripheral
nerve function and osteogenesis [24–26]. Brain myo-inositol depletion in mice missing the
Na+/myo-inositol cotransporter leads to central apnea that is prevented by myo-inositol
supplementation [24, 27].

Author Manuscript

There is no significant correlation between fetal and maternal serum myo-inositol
concentrations. Maternal concentrations are stable in pregnancy, while fetal concentrations
are five times as high as maternal concentrations in the first trimester and decrease during
gestation. Umbilical cord concentrations are higher in the artery than in the vein, consistent
with fetal synthesis [3, 28, 29]. Quirk et al. found activity of glucose-6-phosphate:
inositol-1-phosphate cyclase, a putative regulatory enzyme in myo-inositol synthesis, in
human fetal liver and lung and in placenta [29]. High concentrations of fetal myo-inositol in
early pregnancy may help maintain redox potential in low-oxygen environment in the first
trimester and prevent neural tube defects [30, 31]. Myo-inositol affects surfactant
composition by increasing phosphatidylinositol and the ratio of diphosphatidyl-choline to
sphingomyelin while decreasing phosphatidyl-glycerol [32–34]. Sex-related differences in
composition of surfactant, including a higher proportion of phosphatidylinositol and GAdependent progressive increase in ratio of phosphatidyl-choline to sphingomyelin in male
preterm infants, may contribute to the sex-related difference in respiratory distress syndrome
[35]. Phosphatidylinositol specific phospholipase C, coupled to diacylglycerol lipase action,
could provide a mechanism for the release of arachidonic acid for prostaglandin biosynthesis
during parturition [36].

Author Manuscript

The rate of endogenous production of myo-inositol in 23–29 week preterm infants at 0.44 ±
1.15 weeks of age (0.36 mmol × kg−1 × d−1) is in the range of the amount ingested when
receiving full enteral feeds (average in two studies 0.36 and 0.68 mmol × kg−1 × d−1 in
colostrum and 0.21 and 0.30 mmol × kg−1 × d−1 in HM) [5, 6, 10]. In contrast, the rate of
endogenous production of myo-inositol in term and late preterm infants (1.52 mmol × kg−1
× d−1) far exceeds the amount a breast-fed infant typically ingests [4–6, 37].

Myo-inositol clearance by the kidney involves both glomerular filtration and catabolism in
the parenchyma by myo-inositol oxygenase and aldehyde reductase [38–40]. Urinary myoinositol excretion, large at birth, decreases progressively in parallel with decreasing serum
concentrations and with maturation of aldehyde reductase in the proximal tubule [14]. The
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premature fetus likely secretes myo-inositol-rich urine into the amniotic fluid that is
swallowed and recycled back into the fetus [1]. It is not known whether prolonged rupture of
the fetal membranes or some other pregnancy complication leads to myo-inositol depletion
at very premature birth. In the present study, 20% of infants born before 30 weeks of
gestation had cord blood concentrations that were not quantifiable (i.e., BQL μmol/L). In a
randomized trial, intravenous myo-inositol supplementation starting at 4 to 12 h after birth
resulted in a remarkable increase in serum myo-inositol and decrease in severity of
respiratory distress [31]. Since most of the infants born with a mean gestation of 28 weeks in
this early trial received neither antenatal steroids nor surfactant, these results are not
replicated at present.
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Previous studies have shown an inverse relationship between serum concentrations of myoinositol and severe retinopathy of prematurity [41]. This led to a series of pilot trials and
then a large randomized trial of myo-inositol supplementation, starting from a mean age of
2.8 days and continuing up to 10 weeks, which eventually did not show a benefit [9–11].
Strengths of this study include large sample size, rigorous methods designed to find the best
model to fit the data, multivariate analysis including GA, PMA, and feeding category, and
multiple centers.
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One limitation of the study is that samples were measured in 2006 using an HPLC method
with overlap between BQL threshold (100 μmol/L) and expected blood concentration (~30–
250 μmol/L [3, 4]), resulting in a high proportion of values that were ND or BQL. This may
have resulted in a bias with higher levels of median concentration in samples that were
quantified. A more recent technique has been described, in which myo-inositol is separated
from glucose and other hexose monosaccharides using a lead-form resin-based column and
measurement using liquid chromatography-double mass spectrometry allows accurate and
precise measurements of low myo-inositol concentrations below 50 μmol/L [42]. Additional
limitations of the study include a small number of cord blood samples, a lack of separation
of umbilical arterial and venous blood, lack of prospective data collection at rigorous time
points, missing samples, lack of measurement of myo-inositol in HM or formula, lack of
assessing changes in myo-inositol concentration over time, and lack of analysis by race/
ethnicity. Thus, it is possible that we may have missed significant differences between
groups.
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In summary, in the absence of myo-inositol supplementation, cord myo-inositol
concentrations decreased with increasing GA. Postnatal concentrations decreased with
increasing PMA and were higher among infants who were feeding compared to those who
remained NPO. Present and previous data [8, 31] suggest that in some cases serum
concentrations of myo-inositol at birth are low.
Data availability
Data reported in this paper may be requested through a data use agreement. Further details
are available at https://neonatal.rti.org/index.cfm?fuseaction=DataRequest.Home.
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Fig. 1. Cord myo-inositol concentration with prediction curves resulting linear regression models
of natural log-transformed myoinositol concentration with left censoring by gestational age at
birth (weeks).
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Left-censored includes BQL, below quantifiable limit (<100 μmol/L), and not detected, 0–50
μmol/L.
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Fig. 2. Serial myo-inositol concentration with prediction curves resulting linear regression models
of natural log-transformed myoinositol concentration with left censoring by PMA (weeks) and
feeding category (enterally fed, upper panel; NPO, lower panel).

Left-censored includes BQL, below quantifiable limit (<100 μmol/L), and not detected, 0–50
μmol/L. For the linear model, a random effect for infant was included to account for
correlation between observations within infant.

J Perinatol. Author manuscript; available in PMC 2021 February 18.

Author Manuscript

Author Manuscript

Author Manuscript
34

133

25

27

28

53

1–7 days

120

18

31

35

36

8–21 days

88

3

17

33

35

22–42 days
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2
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43–70 days
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162

Total

A target of seven samples was sought for each of the four gestational age groups, at five postnatal age ranges. In addition, for the youngest two GA groups, a similar target sample was sought in the four
feeding categories. The feeding categories were defined, based on intake in the last 72 h prior to sampling, as exclusive intravenous (IV) feeding (nothing per os, NPO), >80% formula, >80% human milk
[HM], or mixed IV/HM/formula).
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7
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Postnatal age

24–26
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Number of blood samples in predefined gestational age and postnatal age groups obtained for inositol concentrations.

Author Manuscript

Table 1
Brion et al.
Page 13

J Perinatol. Author manuscript; available in PMC 2021 February 18.

Brion et al.

Page 14

Table 2

Author Manuscript

Demographics and sample description.
Infant characteristic

Statistic/category

All infants (N = 281)

Gestational age (weeks)

Mean (SD)

30.4 (4.9)

Median (Q1, Q3)

29.0 (26.3, 33.7)

SGA

33 (12%)

AGA

244 (87%)

LGA

4 (1%)

Female

131 (47%)

Size

Gender

Author Manuscript

Male

150 (53%)

Number of samples

Median (Min, Max)

1 [1, 8]

Sample characteristic

Statistic/category

All samples (N = 441)

Postmenstrual age (weeks)

<27

74 (17%)

27–29

91 (21%)

30–35

177 (40%)

36–45

99 (22%)

Serum

80 (18%)

Plasma-EDTA

33 (7%)

Plasma-heparin

328 (74%)

Cord

34 (8%)

Infant

407 (92%)

Anticoagulant use

Sample type

Q1 first quartile, Q3 third quartile, SGA small for gestational age, AGA appropriate for gestational age, LGA large for gestational age, EDTA
ethylenediamine-tetraacetatic acid.
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0.09 (0.02)
−0.15 (0.02)
0.41 (0.09)

GA (Week)
PMA (Week)
Feeding vs. NPO

Model 2: Postnatal

% Increase in geometric mean for Feeding vs. NPO

% Change for 1-week change in PMA

% Change for 1-week change in GA

% Change for 1-week change in GA

Derived estimate

51.0%

−14.3%

9.2%

−11.9%

Derived estimate

<0.001

<0.001

<0.001

0.003

Type 3 P values

SE standard error, GA gestational age, PMA postmenstrual age, NPO nothing per os.

Feeding includes formula only, human milk only, or mixed intake. Natural log-transformed inositol concentration was modeled using linear regression models with left censoring to account for
concentrations that were not detected or below quantifiable limits. Separate models were used for cord and postnatal samples. For postnatal/serial samples, a random effect for infant was included to account
for correlation between observations within infant. The derived estimate converts the Parameter Estimate to a percent change per week in inositol concentration.

−0.13 (0.04)

GA (Week)

Model 1: Cord

Parameter estimate (SE)

Factor

Model by type of sample
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Modeling results for natural log-transformed inositol concentration.

Author Manuscript

Table 3
Brion et al.
Page 15

J Perinatol. Author manuscript; available in PMC 2021 February 18.

